Experimental Drug Generates Immune Response Against Pancreatic Cancer in People at High Risk

Researchers at Johns Hopkins report that an experimental drug targeting one of the most common genetic drivers of pancreatic cancer was safe in humans, and generated durable immune responses aimed at preventing the cancer in people at high risk. Pancreatic cancer has one of the lowest survival rates of any form, and the developers believe